SGMT · Nasdaq · CIK 0001400118

Sagimet Biosciences Inc.

Sagimet Biosciences Inc.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 22, 2026. Its EDGAR record lists 26 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$51.0M
Form 4 filings on record, past 12 months
26

Company overview

Legal name (as filed)
Sagimet Biosciences Inc.
Ticker
SGMT
SEC Central Index Key (CIK)
0001400118
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
FOSTER CITY, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2680 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Sagimet Biosciences Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2022$2.0MFY2023n/aFY2024n/aFY2025
Net income
-$30.5MFY2022-$27.9MFY2023-$45.6MFY2024-$51.0MFY2025
SGMT annual results
ItemFY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—$2.0M——
Net income-$30.5M-$27.9M-$45.6M-$51.0M
Diluted EPS-$165.20-$2.66-$1.45-$1.58
Total assets$33.0M$96.7M$160.3M$116.5M
Cash and equivalents$158.0K$75.1M$75.8M$35.0M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SGMT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 11, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 22, 20268-KRegulation FD disclosure· period Oct 22, 2026Document · Index
Apr 21, 2026DEF 14ADefinitive proxy statement· period Jun 12, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Sagimet Biosciences Inc., by form type:

4 ×168-K ×12144 ×3SCHEDULE 13G ×3424B5 ×210-Q ×23 ×1424B3 ×1
SGMT recent filings
FiledFormWhat it isOriginal
Oct 22, 20268-KRegulation FD disclosure· period Oct 22, 2026Document · Index
Oct 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Oct 1, 20268-KMaterial agreement· period Sep 30, 2026Document · Index
Oct 1, 2026424B5424B5Document · Index
Sep 30, 20268-KRegulation FD disclosure; Other events· period Sep 30, 2026Document · Index
Sep 30, 2026424B3424B3Document · Index
Aug 17, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 14, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 13, 20268-KOther events· period Aug 13, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 11, 2026Document · Index
Aug 11, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 11, 20268-KResults of operations; Regulation FD disclosure· period Aug 11, 2026Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 30, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 21, 20268-KRegulation FD disclosure· period Jul 20, 2026Document · Index
Jul 20, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 15, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 12, 2026Document · Index
Jun 12, 20268-KDirector or officer change; Shareholder vote results· period Jun 12, 2026Document · Index
Jun 3, 20268-KDirector or officer change· period May 28, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
Jun 1, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
May 14, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 20, 2026Document · Index
May 14, 20263Initial statement of beneficial ownership· period Apr 20, 2026Document · Index
May 12, 20268-KResults of operations· period May 12, 2026Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 28, 20268-KMaterial agreement· period Apr 27, 2026Document · Index
Apr 28, 2026424B5424B5Document · Index
Apr 27, 20268-KRegulation FD disclosure· period Apr 27, 2026Document · Index
Apr 27, 20268-KResults of operations; Regulation FD disclosure; Other events· period Apr 27, 2026Document · Index

Insider filing activity

26 Form 4 filings appear in Sagimet Biosciences Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001400118 and XBRL company facts. Sagimet Biosciences Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.